Publications & Posters
Scholarly publications
Spinal Muscular Atrophy
Apitegromab
May 2021
Advances in Therapy
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
Spinal Muscular Atrophy
Apitegromab
April 2021
2021 Virtual American Academy of Neurology (AAN) Annual Meeting
A Phase 2 Study to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients with Later-Onset Spinal Muscular Atrophy (TOPAZ): Interim Analysis Results
Immuno-Oncology
SRK-181
April 2021
American Association for Cancer Research (AACR) Annual Meeting 2021
Development of a Comprehensive Biomarker Strategy to Support the Latent TGFβ1 Inhibitor SRK-181 Phase 1 Clinical Trial, DRAGON
Immuno-Oncology
SRK-181
March 2021
International Journal of Toxicology
Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
Spinal Muscular Atrophy
Apitegromab
March 2021
2021 MDA Virtual Clinical & Scientific Conference
Apitegromab, a Novel High-Affinity Anti-proMyostatin Monoclonal Antibody for Treating Spinal Muscular Atrophy: Results of a Phase 2 Interim Analysis (Presentation)
Spinal Muscular Atrophy
Apitegromab
March 2021
2021 MDA Virtual Clinical & Scientific Conference
